P16 (CDKN2) IS A MAJOR DELETION TARGET AT 9P21 IN BLADDER-CANCER

Citation
Mp. Williamson et al., P16 (CDKN2) IS A MAJOR DELETION TARGET AT 9P21 IN BLADDER-CANCER, Human molecular genetics, 4(9), 1995, pp. 1569-1577
Citations number
37
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Genetics & Heredity",Biology
Journal title
ISSN journal
0964-6906
Volume
4
Issue
9
Year of publication
1995
Pages
1569 - 1577
Database
ISI
SICI code
0964-6906(1995)4:9<1569:P(IAMD>2.0.ZU;2-M
Abstract
The p16 gene has been identified as a candidate tumour suppressor gene at 9p21, a region commonly deleted in bladder cancer. We screened 140 bladder tumours and 16 cell lines for deletions and sequence variants of p16. Eight cell lines showed homozygous deletion of p16 and two ha d small sequence variations. All 13 tumours with small defined deletio ns of 9p21, 18/31 (58%) of tumours with monosomy 9 and 9/91 (10%) of t umours with no chromosome 9 loss of heterozygosity had homozygous dele tion of p16. No tumour-specific sequence variants were identified. Del etion mapping revealed a nested set of deletions focused on p16. Six d eletions involved p16 but not the related and adjacent gene p15 and on e tumour had an intragenic deletion of p16. All other deletions involv ed both p16 and p15. We conclude that p16 represents the major target for deletion at 9p21 in bladder cancer.